Rapid Micro Biosystems, Inc. Class A ( (RPID) ) has released its Q2 earnings. Here is a breakdown of the information Rapid Micro Biosystems, Inc. Class A presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rapid Micro Biosystems, Inc. is a life sciences technology company that provides automation solutions for microbial quality control in pharmaceutical manufacturing, enhancing the efficiency and safety of healthcare product releases. In its second quarter of 2025 financial report, the company announced a 10% increase in total revenue, reaching $7.3 million, compared to the same period in 2024. This growth was driven by an 18% increase in service revenue and a 6% rise in product revenue.
Key financial highlights include a gross margin improvement to 4% from a negative margin in the previous year, and a decrease in total operating expenses by 6%. Despite these positive trends, the company reported a net loss of $11.9 million, slightly lower than the $12.6 million loss in the second quarter of 2024. Additionally, Rapid Micro Biosystems secured a $45 million term loan facility, with $20 million funded upfront, aimed at strengthening its financial position.
The company continues to focus on expanding its Growth Direct system placements and improving manufacturing efficiency. It reaffirmed its full-year 2025 revenue guidance of at least $32 million, indicating confidence in its strategic direction and market demand.
Looking ahead, Rapid Micro Biosystems remains committed to its strategic priorities, including achieving positive cash flow and enhancing shareholder value through long-term revenue growth and gross margin expansion.